Initial treatments are underway in randomized study of Acorn’s personalized autologous injectable for improving facial ...

Lydian Cosmetic Surgery Clinic in Seoul announces its autologous regenerative therapies, including stem cell and exosome ...

Among patients with multiple myeloma (MM) undergoing autologous stem cell transplantation (ASCT), atrial fibrillation (AF) is a frequent and high-risk complication, according to a study published ...

The study found no significant OS or PFS improvement with auto-HCT plus Rituxan versus Rituxan alone in MCL patients in first complete remission with undetectable MRD. Three-year OS rates were 82.1% ...

Autologous stem cell transplantation (ASCT) is an established consolidation therapy for patients with relapsed or refractory lymphoma. In this procedure, high-dose chemotherapy is administered to ...

In this study, researchers aimed to determine whether BCMA-directed CAR T-cell therapy is a feasible first-line option for newly diagnosed multiple myeloma patients who are ineligible for ASCT.

A diagnosis of acquired von Willebrand disease and stage 2 multiple myeloma followed unusual symptoms, leading to extensive testing. Treatment included a four-drug chemotherapy regimen and an ...

Rapid advances have revolutionized the treatment of multiple myeloma, providing better disease control and prolonging survival. Patients are living years longer, thanks to novel combination therapies ...

Transplanted autologous corneal stem cells successfully repaired corneal injuries in patients. Over 90% of patients achieved complete or partial success. The procedure proved safe with no serious ...

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant (ASCT) for patients with mantle cell lymphoma (MCL) in remission following ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last ...